NanoString Technologies, Inc.

Members of the US Food and Drug Administration Oncologics Drug Advisory Committee who received conflict-of-interest waivers to participate in the agency’s recent three-day meeting to review the accele

Myriad Genetics Inc. finished a busy year with the announcement that the UK's National Institute for Health and Care Excellence (NICE) now recommends Myriad's EndoPredict multigene breast cancer

Immuno-oncology represents a paradigm shift in cancer treatment, with the first wave of PD-1/PD-L1 checkpoint inhibitors such as Opdivo (nivolumab, from Bristol-Myers Squibb Co. ) and Keytruda (

With multiple modalities of care for cancer patients, oncology treatment decision-making has always been complex, but accelerating innovation is driving exponential growth in treatment complexity. Gen